650 results on '"Raggi, D"'
Search Results
2. Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆
3. Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study
4. Defining intermediate-risk non-muscle invasive bladder cancer: A comparative study of EAU and IBCG criteria
5. The effect of metabolic syndrome on long-term renal function after partial nephrectomy
6. The role of androgen response pathway in association with tumor biology and response to neoadjuvant Immune-Checkpoint Inhibitors (ICI) in Muscle-Invasive urothelial Bladder Carcinoma (MIBC)
7. Cancer control rates in adequate versus inadequate treatment with adjuvant immunotherapy instillations with BCG
8. Identifying the optimal definition of PSA response after metastasis directed therapy in men with oligo-recurrent prostate cancer detected at PSMA PET
9. Impact of neoadjuvant chemo-immunotherapy on intra and post operative outcomes in patients with bladder cancer treated with radical cystectomy and pelvic lymph node dissection: Prospective surgical assessment from the NURE-Combo Trial
10. Comprehensive Genomic Profiling (CGP) of clinical T2-4N0M0 Muscle-Invasive Bladder Cancer (MIBC) treated with neoadjuvant pembrolizumab or cisplatin-based chemotherapy before Radical Cystectomy (RC)
11. First results of NURE-Combo: A phase 2 study of neoadjuvant Nivolumab (NIVO) and Nab-Paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with Muscle-Invasive Bladder Cancer (MIBC)
12. 27P Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with cabozantinib (CABO) plus durvalumab (DURVA): Preliminary analysis from the phase II ARCADIA trial
13. 26P Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to cabozantinib (CABO) plus durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the phase II ARCADIA trial)
14. 2370P Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)
15. Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial
16. Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma
17. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis
18. Spezifische Genexpressionsmuster identifizieren Patienten, die in der PURE-01-Studie nach neoadjuvantem Pembrolizumab und radikaler Zystektomie ein Rezidiv erlitten
19. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes
20. Cognitive Analysis for Representation Change
21. Oruga: An Avatar of Representational Systems Theory
22. High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study
23. Tailoring the optimal use of androgen-deprivation therapy concomitant to post-operative radiotherapy among men with pN1 prostate cancer. Long-term results of a large, single Institution series
24. Impact of neoadjuvant immune-checkpoint inhibitor on intra and post operative outcomes in patients with muscle-invasive bladder cancer treated with radical cystectomy
25. Utility of pre- and post-pembrolizumab (Pembro) Vesical Imaging–Reporting and Data System (VI-RADS) to predict the pathological response in muscle-invasive urothelial bladder cancer (MIBC): An analysis of the PURE-01 cohort
26. OP20 Three year-survival outcomes after neoadjuvant pembrolizumab and radical cystectomy: Final results from the PURE-01 study
27. Administration of high-dose chemotherapy with stem cell support in patients 40 years of age or older with advanced germ cell tumours: a retrospective study from the European Society for Blood and Marrow Transplantation database
28. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party
29. 153P Efficacy and toxicity of HER2-targeted antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review
30. Three year-survival outcomes after neoadjuvant pembrolizumab and radical cystectomy: final results from the pure-01 study
31. Neglected lymph nodal metastases in patients with renal cancer: when to extend the anatomical template of lymph node dissection during nephrectomy
32. The impact of variant histology on the probability of lymph node involvement at imaging: CT scan vs FDG PET
33. When is neoadjuvant androgen deprivation therapy beneficial for highly aggressive prostate cancer before radical prostatectomy? implications for multi-modal tailored approaches and trials design
34. Impact of 68Ga-PSMA PET/CT and metastasis-directed therapy on clinical recurrence in patients with biochemical recurrence after radical prostatectomy. results from a single center series
35. Oncologic outcomes in patients diagnosed with PT3A non-metastatic renal cell cancer according to renal vein thrombus or fat invasion
36. Optimizing timing and indications for 68Ga-PSMA PET/CT in patients with biochemical recurrent prostate cancer after radical prostatectomy
37. The role of FDG PET in the staging of bladder cancer patients candidate for radical cystectomy
38. When to de-intensify oncologic surveillance scheme for non-clear cell renal cell carcinoma
39. The impact of histological variants on the performance characteristics of 68Ga-PSMA PET/CT in the primary and recurrent setting
40. Application of the keynote-564 trial results to real life population: which patients with advanced kidney cancer should receive adjuvant pembrolizumab
41. Imaging intensity after surgery for clear cell renal cell carcinoma
42. When node-positive prostate cancer should be considered a systemic disease? assessing the prognostic role of preoperative 68Ga-PSMA PET/ CT results in patients with lymph node invasion at final pathology
43. The added value of histological subtype in the prediction of oncologic outcomes in patients with non-metastatic papillary renal cell carcinoma
44. How to maximize the diagnostic rate of endoscopic biopsy during flexible ureteroscopy for upper tract urothelial carcinoma
45. 1738P Three-year follow-up update and survival outcomes of the PURE-01 study
46. Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes
47. 2014P Overall survival (OS) results in phase II trial of cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (ARCADIA)
48. 1981P Cabozantinib plus durvalumab in patients with advanced and chemotherapy-treated urothelial carcinoma (UC) and variant histology (VH): An open-label, phase II, single-arm proof-of-concept trial: ARCADIA study. Subgroup analysis for bone metastasis
49. 695P Assessment of the utility of CT scans in the long-term follow-up of metastatic non-seminomatous germ cell tumours (mNSGCT): The Late CT study
50. Cross-domain correspondences for explainable recommendations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.